Eisai Presents the Latest Data from the Phase 2b Open-Label Extension Study of BAN2401 at AAIC 2020
Details : The clinical study design of the newly initiated Phase III clinical study evaluating BAN2401 for preclinical Alzheimer’s disease (AD) patients will be presented orally.
Product Name : BAN2401
Product Type : Large molecule
Upfront Cash : Not Applicable
July 30, 2020
Details : The safety and efficacy results from a Phase II clinical study on lemborexant (orexin receptor antagonist) targeting Irregular Sleep Wake Rhythm Disorder (ISWRD) associated with AD will be presented.
Product Name : BAN2401
Product Type : Large molecule
Upfront Cash : Not Applicable
July 22, 2020
Alzheimer Patients at Swedish Clinics to be Included in Phase 3 Study of Drug Candidate BAN2401
Details : The enrollment of patients with early Alzheimer's disease will be carried out at memory clinics at four Swedish university hospitals.
Product Name : Undisclosed
Product Type : Large molecule
Upfront Cash : Not Applicable
March 03, 2020
Reset All
